论文部分内容阅读
血管生长因子基因转移诱导的血管新生已成为治疗心肌缺血的一种新的思路.重组腺病毒介导的肝细胞生长因子基因转移能够有效诱导治疗性血管新生.为评价重组腺病毒肝细胞生长因子基因(Ad-HGF)转移治疗冠心病效果,本实验利用Ameroid缩窄环建立了小型猪慢性心肌缺血的研究模型,并评价了Ad-HGF对慢性心肌缺血的治疗作用.18只小型猪随机分成3组:手术对照组、模型组和治疗组.模型组和治疗组分别在回旋支近端放置Ameroid缩窄环,模型成功后分别直接注射安慰剂和Ad-HGF到缺血心肌部位进行治疗.治疗4周后对心功能和血液供应的改善进行了评价.结果表明,与对照组和模型组相比,Ad-HGF组的心肌灌注有了明显改善.在治疗后4周,Ad-HGF组新形成的血管密度和血管数量明显高于模型组.Ad-HGF组心肌缺血面积明显减少,左心室射血分数显著改善.这些结果为肝细胞生长因子基因治疗慢性心肌缺血提供了直接的证据.
Angiogenesis induced by gene transfer of vascular growth factor has become a new way to treat myocardial ischemia. Recombinant adenovirus-mediated hepatocyte growth factor gene transfer can effectively induce therapeutic angiogenesis. To evaluate the effect of recombinant adenovirus hepatocyte growth (Ad-HGF) in the treatment of coronary heart disease, the experimental use of Ameroid narrowing ring established mini-pig chronic myocardial ischemia model, and evaluate the Ad-HGF treatment of chronic myocardial ischemia .18 small The pigs were randomly divided into three groups: operation control group, model group and treatment group.The Ameroid constriction ring was placed on the proximal side of the circumflex artery in the model group and the treatment group, respectively. After successful injection, placebo and Ad-HGF were directly injected into ischemic myocardium And the improvement of cardiac function and blood supply was evaluated after 4 weeks of treatment.The results showed that myocardial perfusion of Ad-HGF group was significantly improved compared with control group and model group.At 4 weeks after treatment, Ad -HGF group newly formed vascular density and blood vessel number was significantly higher than the model group.Ad-HGF group myocardial ischemic area was significantly reduced, left ventricular ejection fraction was significantly improved.These results for the hepatocyte growth factor-based Treatment of chronic myocardial ischemia provides direct evidence.